{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:21:29Z","timestamp":1780514489353,"version":"3.54.1"},"reference-count":19,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2013,1,25]],"date-time":"2013-01-25T00:00:00Z","timestamp":1359072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2013,6]]},"abstract":"\n Aims<\/jats:title>\n \n The objective was to assess the consistency of effect of switching to ezetimibe\/simvastatin 10\/20\u2009mg versus doubling the baseline statin dose (to simvastatin 40\u2009mg or atorvastatin 20\u2009mg) or switching to rosuvastatin 10\u2009mg across subgroups of subjects with (n\u2009=\u2009617) and without (n\u2009=\u2009191) metabolic syndrome (\n MetS<\/jats:styled-content>\n ).\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n This was a\n post hoc<\/jats:italic>\n analysis of a randomized, double\u2010blind, 6\u2010week study of adults 18\u201379\u2009years with cardiovascular disease and diabetes mellitus with low\u2010density lipoprotein cholesterol (\n LDL<\/jats:styled-content>\n \u2010C) \u226570 and \u2264160\u2009mg\/dl. The percent change in\n LDL<\/jats:styled-content>\n \u2010C and other lipids was estimated within each subgroup separately. Safety and tolerability were assessed.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n In subjects with\n MetS<\/jats:styled-content>\n , percent changes in\n LDL<\/jats:styled-content>\n \u2010C and other lipids were greater with ezetimibe\/simvastatin versus doubling baseline statin or numerically greater versus switching to rosuvastatin, except high\u2010density lipoprotein cholesterol and apolipoprotein (Apo)\n AI<\/jats:styled-content>\n (mean percent changes in\n LDL<\/jats:styled-content>\n \u2010C were: \u221222.49% ezetimibe\/simvastatin, \u22129.64% doubled baseline statin and \u221219.20% rosuvastatin). In subjects without\n MetS<\/jats:styled-content>\n , percent changes in\n LDL<\/jats:styled-content>\n \u2010C, total cholesterol and Apo B were greater with ezetimibe\/simvastatin versus doubling baseline statin or numerically greater versus switching to rosuvastatin (mean percent changes in\n LDL<\/jats:styled-content>\n \u2010C were: \u221225.14% ezetimibe\/simvastatin, \u22124.75% doubled baseline statin and \u221219.75% rosuvastatin). Safety profiles were generally similar.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n These results showed that switching to ezetimibe\/simvastatin 10\/20\u2009mg was more effective at reducing\n LDL<\/jats:styled-content>\n \u2010C, total cholesterol and Apo B versus doubling the baseline statin dose to simvastatin 40\u2009mg or atorvastatin 20\u2009mg or switching to rosuvastatin 10\u2009mg regardless of\n MetS<\/jats:styled-content>\n status. These results were generally similar to those of the full cohort.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/dom.12059","type":"journal-article","created":{"date-parts":[[2012,12,26]],"date-time":"2012-12-26T14:03:54Z","timestamp":1356530634000},"page":"513-522","source":"Crossref","is-referenced-by-count":7,"title":["The efficacy and safety of ezetimibe\/simvastatin combination compared with intensified lipid\u2010lowering treatment strategies in diabetic subjects with and without metabolic syndrome"],"prefix":"10.1111","volume":"15","author":[{"given":"J. G.","family":"Jimenez","sequence":"first","affiliation":[{"name":"Hospital CIMA San Jose Escazu and Universidad de Ciencias Medicas Sabana Oeste San Jose Costa Rica"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. B.","family":"Rosen","sequence":"additional","affiliation":[{"name":"Clinical Research of South Florida Coral Gables FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Pirags","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Latvia Riga Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Massaad","sequence":"additional","affiliation":[{"name":"MSD Belgium Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. E.","family":"Hanson","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme Corp. Whitehouse Station NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Brudi","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme Corp. Whitehouse Station NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Triscari","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme Corp. Whitehouse Station NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,1,25]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807233390404"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812033392314"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/68.4.899"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-9018"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000111245.75752.C6"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.19.2486"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0828-282X(09)70715-9"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjr.0000277984.31558.c4"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079907X210507"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2009.05.003"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2008.02.002"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2009.01152.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/1479164112465212"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/1479164111418136"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1762"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.3132\/dvdr.2006.020"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13556-011-0001-8"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.08.038"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.4065\/81.12.1579"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12059","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12059","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:40:45Z","timestamp":1761882045000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,25]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["10.1111\/dom.12059"],"URL":"https:\/\/doi.org\/10.1111\/dom.12059","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,25]]}}}